The InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 million and EUR 75 million, to innovative players active in developing or manufacturing vaccines, medicines, medical and diagnostic devices, and research infrastructure to combat infectious diseases.

Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.

The product is being made available directly through the European Investment Bank.

The InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 million and EUR 75 million, to innovative players active in developing or manufacturing vaccines, medicines, medical and diagnostic devices, and research infrastructure to combat infectious diseases.

Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.

The product is being made available directly through the European Investment Bank.